DSS Expands Nutraceutical Product Lines through Impact BioMedical’s Investment in Nano Nutraceutical Contract Manufacturer ...
Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE
American: DSS), a multinational company operating businesses
focusing on brand protection technology, blockchain security,
direct marketing, healthcare, real estate, and securitized digital
assets, today announced its wholly owned subsidiary Impact
BioMedical, Inc. (“Impact BioMedical”) entered into an investment
and distribution agreement with Nano9 Labs, LLC (“Nano9”), an
R&D and contract manufacturing company specializing in the
development of nano-sized nutraceutical products and ingredients.
“Impact BioMedical’s investment in Nano9 will
enable us to add multiple private-labeled nutraceutical product
lines to our RBC Life and HWH World subsidiaries,” stated Frank D.
Heuszel, CEO of DSS. “We expect Nano9’s nutraceutical delivery
technology to greatly strengthen the competitive advantage of our
growing direct marketing distributor network, both in the U.S. and
across Asia. Our direct selling segment was a key driver of revenue
growth for DSS in 2020, and we expect this trend to accelerate in
2021 and beyond.”
“Nano9 is very excited about the newly formed
relationship with Impact BioMedical," said founder Dr. Tracy Gibbs.
“Our technology and product lines are growing fast in the U.S. With
this new partnership, we can now grow and expand the benefits of
nano technology in Asian markets as well.”
Nano9’s proprietary three-stage process enables
the creation of nano particles out of ingredients that
traditionally have low to no bioavailability.
“We believe our technology represents a paradigm
shift in delivery technology for the nutraceutical industry. By
using nano technology, we can change the way nutrients are
delivered to our cells by dramatically increasing the
bioavailability of ingredients while simultaneously increasing
efficacy,” added Dr. Gibbs.
“Combining innovative nutraceutical products
with our established direct selling infrastructure affords us the
opportunity to rapidly monetize this investment, while the addition
of multiple new product lines further strengthens the overall value
of Impact BioMedical,” commented Jason Grady, COO of DSS.
Founded in 2018, and after two years of
improving its technology, Nano9 launched its first product to
market in the spring of 2020. Currently Nano9 produces products for
16 companies in four countries.
The U.S. nutraceutical market was
worth approximately $71 billion in 2017 and is forecasted to reach
$133 billion by 2025, according to Statista. Globally, the
nutraceutical market is growing at a 7.8% CAGR and is expected to
reach $336 billion by 2023, according to BCC Research.
About Impact BioMedical,
Inc.Impact BioMedical, Inc. ("Impact BioMedical") is a
wholly owned subsidiary of DSS. Impact BioMedical strives to
leverage its scientific know-how and intellectual property rights
to provide solutions that have been plaguing the biomedical field
for decades. By tapping into the scientific expertise of GRDG
Sciences, LLC, and other partners, Impact BioMedical pledges to
undertake a concerted effort to deliver unique offerings in human
healthcare and wellness. For more information on Impact BioMedical
About Document Security Systems, Inc.
DSS is a multinational company operating
businesses focused on brand protection technology, blockchain
security, direct marketing, healthcare, real estate, and
securitized digital assets. Its business model is based on a
distribution sharing system in which shareholders will receive
shares in its subsidiaries as DSS strategically spins them out into
IPOs. Its historic business revolves around counterfeit deterrent
and authentication technologies, smart packaging, and consumer
product engagement. DSS is led by its Chairman and largest
shareholder, Mr. Fai Chan, a highly successful global business
veteran of more than 40 years specializing in corporate
transformation while managing risk. He has successfully
restructured more than 35 corporations with a combined value of $25
For more information on DSS visit http://www.dsssecure.com.
Dave Gentry, CEORedChip Companies
Safe Harbor Disclosure
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements include, but are not
limited to, statements related to the Company's intended use of
proceeds and other statements that are not historical facts.
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that may
cause actual results or events to differ materially from those
projected. These risks and uncertainties, many of which are beyond
our control, include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of development activities; our ability to attract,
integrate and retain key personnel; our need for substantial
additional funds; patent and intellectual property matters;
competition; as well as other risks described in the section
entitled "Risk Factors" in the prospectus and in our other filings
with the SEC, including, without limitation, our reports on Forms
8-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.